PCCHA4S Stock Latest News
Private CompaniesCHARM Therapeutics to Present Menin Inhibitor Data at ASH 20265d agoCHA4S
Private CompaniesCHARM Therapeutics Advances Menin Inhibitor Development in AML1w agoCHA4S
Private CompaniesCHARM Therapeutics Advances CHM-029 Into Phase I/II AML Trial1M agoCHA4S
Private CompaniesCHARM Therapeutics Advances Menin Inhibitor Trial and Engages Investors at TechBioUK1M agoCHA4S
Private CompaniesCHARM Therapeutics Advances Menin Inhibitor Into Phase I/II AML Trial1M agoCHA4S
Private CompaniesCHARM Therapeutics Highlights Next-Generation Menin Inhibitor Strategy in AML2M agoCHA4S
Private CompaniesCHARM Therapeutics Highlights Progress in Menin Inhibitor Program at EHA Congress5M agoCHA4S
Private CompaniesCHARM Therapeutics Advances AI-Driven Menin Inhibitor Toward Clinical Stage in AML5M agoCHA4S
Private CompaniesCharm Therapeutics Targets Next-Generation Menin Inhibition for AML5M agoCHA4S
Private CompaniesCHARM Therapeutics Targets Menin Inhibitor Resistance in AML Pipeline5M agoCHA4S
Private CompaniesCharm Therapeutics Highlights Next-Generation Menin Inhibitor Strategy in AML6M agoCHA4S
Private CompaniesCharm Therapeutics Develops Next-Generation Menin Inhibitor Targeting AML Resistance6M agoCHA4S
Private CompaniesCHARM Therapeutics Targets AML Resistance With Next-Generation Menin Inhibitor6M agoCHA4S
Private CompaniesCHARM Therapeutics Advances Next-Generation Menin Inhibitor Strategy in AML6M agoCHA4S
Private CompaniesCHARM Therapeutics – Weekly Recap6M agoCHA4S
Private CompaniesCHARM Therapeutics Highlights Menin Inhibitor Strategy in High-Need AML Market6M agoCHA4SPrivate CompaniesCHARM Therapeutics Emphasizes Menin Inhibitor Strategy in High-Need AML Market6M agoCHA4S




